SAGE stock forecast
Our latest prediction for SAGE Therapeutics, Inc.'s stock price was made on the Dec. 9, 2019 when the stock price was at 62.66$.
In the short term (2weeks), SAGE's stock price should underperform the market by -5.97%. During that period the price should oscillate between -11.81% and +15.47%.
In the medium term (3months), SAGE's stock price should underperform the market by -14.25%. During that period the price should oscillate between -38.20% and +27.23%.Get email alerts
About SAGE Therapeutics, Inc.
SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.
At the moment the company generates 5M USD in revenues.
On its last earning announcement, the company reported a loss of -13.53$ per share.
The book value per share is 23.10$
Three months stock forecastDec. 9, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|